Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Share-based Compensation (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Share-based Compensation data on record, last reported at $249000.0 in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 2666.67% year-over-year to $249000.0; the TTM value through Oct 2025 reached $844000.0, down 7.15%, while the annual FY2025 figure was $654000.0, 41.5% down from the prior year.
  • Share-based Compensation reached $249000.0 in Q4 2025 per CSBR's latest filing, up from $208000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $423000.0 in Q3 2023 and bottomed at $9000.0 in Q4 2024.
  • Average Share-based Compensation over 5 years is $219900.0, with a median of $220000.0 recorded in 2021.
  • Peak YoY movement for Share-based Compensation: tumbled 83.02% in 2024, then skyrocketed 2666.67% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $134000.0 in 2021, then decreased by 11.19% to $119000.0 in 2022, then plummeted by 55.46% to $53000.0 in 2023, then crashed by 83.02% to $9000.0 in 2024, then surged by 2666.67% to $249000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $249000.0 in Q4 2025, $208000.0 in Q3 2025, and $131000.0 in Q2 2025.